The leukemias were transplantable into secondary recipients, and the shorter latency of the TET2-deficient CebpaDM AML was preserved in this setting (Supplemental Fig. 2h–i), indicating that TET2 not only has important tumor suppressive functions during malignant transformation but also during progression of AML. The gene discussed is TET2; the disease is acute myeloid leukemia.